$2.77
2.46% yesterday
Nasdaq, Sep 20, 10:04 pm CET
ISIN
US3632252025
Symbol
GALT
Sector
Industry

Galectin Therapeutics Inc. Stock price

$2.77
+0.47 20.43% 1M
+0.57 25.91% 6M
+1.11 66.87% YTD
+0.99 55.62% 1Y
-0.89 24.32% 3Y
-0.96 25.74% 5Y
-2.47 47.14% 10Y
Nasdaq, Closing price Fri, Sep 20 2024
-0.07 2.46%
ISIN
US3632252025
Symbol
GALT
Sector
Industry

Key metrics

Market capitalization $172.51m
Enterprise Value $242.60m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-39.67m
Free Cash Flow (TTM) Free Cash Flow $-32.78m
Cash position $25.60m
EPS (TTM) EPS $-0.78
Short interest 16.88%
Show more

Is Galectin Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Galectin Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Galectin Therapeutics Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Galectin Therapeutics Inc.:

Buy
100%

Financial data from Galectin Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
0% 0%
-
-0.04 -0.04
-
-
- Selling and Administrative Expenses 5.77 5.77
8% 8%
-
- Research and Development Expense 34 34
6% 6%
-
-40 -40
4% 4%
-
- Depreciation and Amortization 0.04 0.04
-
-
EBIT (Operating Income) EBIT -40 -40
4% 4%
-
Net Profit -44 -44
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galectin Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galectin Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
Neutral
GlobeNewsWire
about one month ago
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024.
Neutral
GlobeNewsWire
about 2 months ago
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately.
More Galectin Therapeutics Inc. News

Company Profile

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease and cancer. Its programs target the development of carbohydrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Head office United States
CEO Joel Lewis
Employees 14
Founded 2000
Website www.galectintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today